Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease
Science Advances · 06.06.2025 · 11 (23)
DOI: 10.1126/sciadv.adv8875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 06.06.2025. Verfasst von Grace Neilsen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 3…. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents, Viral Nonstructural Proteins. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCATS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
E166V in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nsp5 protease confers strong resistance to the antiviral component of Paxlovid, nirmatrelvir (NIR), in passaging and clinical samples. In SARS-CoV-2 replicons, E166V drastically decreased Washington (WA1) but not Omicron (BA.1) fitness (20- versus 2-fold), suggesting a lower barrier to resistance in the BA.1 strain and consistent with observed differences in respective nsp5 dimerization affinities. Crystal structures reveal a steric clash between the rigid, bulky NIR tert -butyl group and the β-branched Val 166 , disrupting the covalent binding of NIR to the catalytic Cys 145 and leading to high resistance in BA.1 and WA1 replicons. NIR-resistant replicons remained susceptible to GC376, which can still covalently bind Cys 145 by avoiding a steric clash with Val 166 through “wiggling and jiggling.” Hence, strategic flexibility is a strategy that will help design second-generation antivirals against NIR-resistant viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
ORCID-Profile: Grace Neilsen, Shuiyun Lan, Ryan L Slack, Zachary C Lorson, Rachel Lee, Jasper Lee, Philip R Tedbury, Karen A Kirby, Raymond F Schinazi, Stefan G Sarafianos
Förderung
- NIGMS NIH HHS
- NCATS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Neilsen, G., Lan, S., Slack, R. L., Lorson, Z. C., Emanuelli Castaner, A., Lee, R., Edwards, K. G., Zhang, H., Lee, J., Cantara, W. A., Cilento, M. E., Zhang, H., De, R., Amblard, F., Tedbury, P. R., Kirby, K. A., Schinazi, R. F., & Sarafianos, S. G. (2025). Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease. Science Advances, 11(23). https://doi.org/10.1126/sciadv.adv8875
Vancouver
Neilsen G, Lan S, Slack RL, Lorson ZC, Emanuelli Castaner A, Lee R, et al. Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease. Science Advances. 2025;11(23). doi:10.1126/sciadv.adv8875
BibTeX
@article{Neilsen2025,
author = {Neilsen, Grace and Lan, Shuiyun and Slack, Ryan L and Lorson, Zachary C and Emanuelli Castaner, Andres and Lee, Rachel and Edwards, Kristin G and Zhang, Huanchun and Lee, Jasper and Cantara, William A and Cilento, Maria E and Zhang, Hongwang and De, Ramyani and Amblard, Franck and Tedbury, Philip R and Kirby, Karen A and Schinazi, Raymond F and Sarafianos, Stefan G},
title = {Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {23},
doi = {10.1126/sciadv.adv8875}
}
EUVIMED